1. Home
  2. POWI vs ACAD Comparison

POWI vs ACAD Comparison

Compare POWI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Power Integrations Inc.

POWI

Power Integrations Inc.

HOLD

Current Price

$86.86

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.24

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POWI
ACAD
Founded
1988
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.8B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
POWI
ACAD
Price
$86.86
$21.24
Analyst Decision
Strong Buy
Buy
Analyst Count
3
22
Target Price
$60.00
$30.55
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
1.23%
N/A
EPS Growth
N/A
69.12
EPS
0.06
0.02
Revenue
$443,504,000.00
$726,437,000.00
Revenue This Year
$8.12
$18.80
Revenue Next Year
$16.54
$11.70
P/E Ratio
$1,399.17
$1,058.75
Revenue Growth
5.86
40.45
52 Week Low
$30.86
$19.69
52 Week High
$84.90
$28.35

Technical Indicators

Market Signals
Indicator
POWI
ACAD
Relative Strength Index (RSI) 73.54 45.81
Support Level $44.24 $20.11
Resistance Level N/A $22.03
Average True Range (ATR) 5.03 0.70
MACD 0.57 -0.05
Stochastic Oscillator 91.77 35.70

Price Performance

Historical Comparison
POWI
ACAD

About POWI Power Integrations Inc.

Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: